PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AN2 Therapeutics Inc (ANTX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$72.19M
EPS-$2.74
Year Range$2.20 - $22.22
Target Price$16.00
Short %3.83%
Short Ratio2.51

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


AN2 Therapeutics Inc

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AN2 Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%December2024FebruaryMarchAprilMay
-85.26%
16.60%
ANTX (AN2 Therapeutics Inc)
Benchmark (^GSPC)

S&P 500

Returns By Period

AN2 Therapeutics Inc had a return of -88.92% year-to-date (YTD) and -72.58% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-88.92%11.05%
1 month-8.10%4.86%
6 months-86.18%17.50%
1 year-72.58%27.37%
5 years (annualized)N/A13.14%
10 years (annualized)N/A10.90%

Monthly Returns

The table below presents the monthly returns of ANTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-5.81%-84.56%9.06%-26.15%-88.92%
202327.60%-7.24%-12.50%-20.47%-28.54%51.52%-4.47%85.22%6.91%-10.32%21.84%16.62%115.01%
2022-2.14%3.72%-4.03%-48.33%10.45%100.23%1.40%-17.03%-30.86%-4.41%-38.12%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ANTX is 15, indicating that it is in the bottom 15% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of ANTX is 1515
ANTX (AN2 Therapeutics Inc)
The Sharpe Ratio Rank of ANTX is 1515Sharpe Ratio Rank
The Sortino Ratio Rank of ANTX is 2525Sortino Ratio Rank
The Omega Ratio Rank of ANTX is 2323Omega Ratio Rank
The Calmar Ratio Rank of ANTX is 66Calmar Ratio Rank
The Martin Ratio Rank of ANTX is 44Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AN2 Therapeutics Inc (ANTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ANTX
Sharpe ratio
The chart of Sharpe ratio for ANTX, currently valued at -0.63, compared to the broader market-2.00-1.000.001.002.003.004.00-0.63
Sortino ratio
The chart of Sortino ratio for ANTX, currently valued at -0.26, compared to the broader market-4.00-2.000.002.004.006.00-0.26
Omega ratio
The chart of Omega ratio for ANTX, currently valued at 0.95, compared to the broader market0.501.001.502.000.95
Calmar ratio
The chart of Calmar ratio for ANTX, currently valued at -0.77, compared to the broader market0.002.004.006.00-0.77
Martin ratio
The chart of Martin ratio for ANTX, currently valued at -1.52, compared to the broader market-10.000.0010.0020.0030.00-1.52
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.49, compared to the broader market-2.00-1.000.001.002.003.004.002.49
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.52, compared to the broader market-4.00-2.000.002.004.006.003.52
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.43, compared to the broader market0.501.001.502.001.43
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 2.03, compared to the broader market0.002.004.006.002.03
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 9.57, compared to the broader market-10.000.0010.0020.0030.009.57

Sharpe Ratio

The current AN2 Therapeutics Inc Sharpe ratio is -0.63. This value is calculated based on the past 12 months of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of AN2 Therapeutics Inc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2024FebruaryMarchAprilMay
-0.63
2.49
ANTX (AN2 Therapeutics Inc)
Benchmark (^GSPC)

Dividends

Dividend History


AN2 Therapeutics Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-89.82%
-0.21%
ANTX (AN2 Therapeutics Inc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AN2 Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AN2 Therapeutics Inc was 89.82%, occurring on May 15, 2024. The portfolio has not yet recovered.

The current AN2 Therapeutics Inc drawdown is 89.82%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-89.82%Aug 16, 2022440May 15, 2024
-59.56%May 9, 202258Aug 1, 20229Aug 12, 202267
-13.49%Apr 5, 20225Apr 11, 202212Apr 28, 202217
-2.6%Mar 28, 20223Mar 30, 20222Apr 1, 20225
-1.82%Apr 29, 20221Apr 29, 20221May 2, 20222

Volatility

Volatility Chart

The current AN2 Therapeutics Inc volatility is 13.01%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%100.00%120.00%140.00%December2024FebruaryMarchAprilMay
13.01%
3.40%
ANTX (AN2 Therapeutics Inc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AN2 Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items